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Regular Article
TRANSPLANTATION
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Key Points
• Immunological tolerance can
be achieved by direct
modulation of the intrinsic
apoptosis pathway in
peripheral lymphocytes.
Induction of mixed hematopoietic chimerism results in donor-specific immunological
tolerance by apoptosis-mediated deletion of donor-reactive lymphocytes. A broad clinical
application of this approach is currently hampered by limited predictability and toxicity of
the available conditioning protocols. We developed a new therapeutic approach to induce
mixed chimerism and tolerance by a direct pharmacological modulation of the intrinsic
apoptosis pathway in peripheral T cells. The proapoptotic small-molecule Bcl-2 inhibitor
ABT-737 promoted mixed chimerism induction and reversed the antitolerogenic effect of
calcineurin inhibitors by boosting the critical role of the proapoptotic Bcl-2 factor Bim. A
short conditioning protocol with ABT-737 in combination with costimulation blockade and low-dose cyclosporine A resulted in
a complete deletion of peripheral donor-reactive lymphocytes and was sufficient to induce mixed chimerism and robust systemic
tolerance across full major histocompatibility complex barriers, without myelosuppression and by using moderate doses of bone
marrow cells. Thus, immunological tolerance can be achieved by direct modulation of the intrinsic apoptosis pathway in peripheral
lymphocytes—a new approach to translate immunological tolerance into clinically applicable protocols. (Blood. 2013;122(9):1669-1677)
Introduction
Induction of allograft tolerance, a state in which the immune system
accepts donor organs but normally responds to foreign antigens,
represents the ideal solution for preventing rejection after solid-organ
transplantation without immunosuppression-related toxicity. Among
the different experimental models to induce tolerance, very few were
successful in large animals and only one strategy—namely, the
induction of mixed chimerism by combined transplantation of a solid
organ and hematopoietic stem cells from the same donor—was
successful in clinical pilot studies.1
The main mechanism of tolerance in mixed chimeras is central
deletion of newly arising donor-reactive lymphocytes induced by
the presence of donor-derived antigen-presenting cells in central
lymphatic organs.2,3 Preexisting mature donor-reactive T cells are
not exposed to this tolerization process and need to be removed
from the T-cell repertoire by a conditioning therapy to prevent
rejection. In the first clinical mixed chimerism studies, peripheral
T-cell tolerization was obtained by unselective lymphocyte depletion
through irradiation or profound T-cell depletion by antibodies.4-7 This
approach was effective, but inevitably induced pancytopenia and with
some protocols also engraftment syndrome. Moreover, in nonhuman
primates and patients, hematopoietic chimerismwas not always stable
over time, and in some protocols chimerism was only transiently
detectable (apparently without precluding tolerance maintenance).4,5
Other groups reported the establishment of full chimerism, a condition
that, however, bears a high risk for graft-vs-host disease.6
The hope for a selective and less toxic option to clonally delete
peripheral donor-reactive T cells was provided by the development of
immunomodulatory strategies based on costimulation blockade.
Blocking CD28/CD80/CD86 and CD154/CD40 signaling induces
anergy and deletional tolerance by activation of the apoptosis cascade
in alloreactive T cells.3,8,9 However, this strategy displayed a reduced
efficacy in combination with standard immunosuppression by cal-
cineurin inhibitors10,11 and was not sufficient to induce tolerance in
case of a high donor-reactive T-cell precursor frequency.12
Resistance to anti-CD154-induced or CTLA4Ig-induced tolerance
in mice overexpressing the antiapoptotic factor Bcl-xL indicates
that the regulation of the intrinsic apoptosis pathway by the
Bcl-2 family is pivotal in this setting.13,14 The recent advent of
selective Bcl-2 family inhibitors offers new pharmacological
options to modulate these physiological processes. Of particular
clinical interest are the small molecules ABT-737 and ABT-263
(navitoclax),15,16 rationally designed molecules with antineoplas-
tic17 and immunomodulatory properties.18-20 ABT-737 acts as
a “sensitizer BH3-only protein”: it inhibits the antiapoptotic Bcl-2
factors Bcl-2, Bcl-xL, and Bcl-w and enhances the effect of
proapoptotic endogenous “activator BH3-only proteins,” such as
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Bid or Bim.15 ABT-737 has a selective proapoptotic activity on
peripheral lymphocytes and platelets, but does not induce myelo-
suppression, as shown by the unaffected numbers of granulocytes
and erythrocytes in peripheral blood.18,20 This activity profile
resulted in a favorable therapeutic index for ABT-263 in first clinical
cancer trials.21 Moreover, ABT-737 inhibited allogeneic immune
responses through apoptosis induction in donor-reactive T cells.20
This effect wasmarkedly increased in combinationwith cyclosporine
A (CsA), because calcineurin inhibition prevented resistance of
activated T cells to ABT-737 in the first days after antigen rec-
ognition by blocking the expression of the antiapoptotic factor Bcl-
2A1, which is not antagonized by ABT-737.22 Furthermore, CsA
reduced the expression of Bcl-2 in lymphocytes and therefore
increased the proapoptotic effect of ABT-737 without affecting its
selectivity profile.23
In this study we evaluated Bcl-2 inhibition as a novel option to
induce donor-specific tolerance in the context of mixed chimerism
protocols. We found that Bcl-2 inhibition promoted tolerance by
supporting the deletion of donor reactive T cells in combination
with costimulation blockade. The tolerogenic effect of ABT-737
on peripheral lymphocytes was mediated by a pharmacological
boosting of the proapoptotic factor Bim, which was identified as
a critical player for establishment ofmixed chimerism.By targeting the
intrinsic apoptosis pathway, we developed a novel protocol to achieve
complete deletion of donor-reactive T cellswith aminimal toxicity and
to induce robust systemic tolerance without myelosuppression,
Methods
Mice
C57BL/6 (B6, H-2b), CBA (H-2k), BALB/c (H-2d), BM3.3 (CBA, H-2k), and
Bim knock-out mice (Bim2/2, H-2b) were housed in specific pathogen-free
conditions at the University of Zu¨rich. The BM3.3 mouse24—which expresses
on all CD8 T cells a transgenic T-cell receptor (TCR) selective for a naturally
processed octapeptide bound to the allogeneic major histocompatibility com-
plex (MHC) class I molecule H-2Kb—was kindly provided by A.-M. Schmitt-
Verhulst.25 Bim2/2 mice were kindly provided by Andreas Strasser.26 All
animal experiments were performed according to protocols approved by
the legal authority (Veterinary Office, Canton of Zu¨rich, Switzerland).
Conditioning and bone marrow (BM) procedures
Different conditioning protocols were tested as indicated. In general, B6-
recipient mice received 1.5 or 3 Gy total body irradiation (TBI) from
a 137Caesium irradiator on day 21 with respect to bone marrow trans-
plantation (BMT). Hamster anti-mouse CD154 (MR1, 2 mg; purchased from
Bio-X-cell, West Lebanon, NH) was administered intraperitoneally (i.p.) 6 to
12 hours before transplantation with 253 106 fully MHC-mismatched CBA
BM cells by tail vein injection. In some experiments, CTLA4Ig (abatacept,
0.5mg; provided by Bristol-Myers Squibb, NewYork, NY) was administered
at day 2 after BMT. ABT-737, provided by Abbott Bioresearch (Worcester,
MA), was dissolved in polyethylene glycol, Tween 80, dextrose solution, and
dimethylsulfoxide and injected intraperitoneally at 50 mg/kg. CsA (Sigma-
Aldrich, Buchs, Switzerland) was dissolved in ethanol and cremaphor EL
(Sigma-Aldrich), then diluted in phosphate-buffered saline and injected
subcutaneously at 10mg/kg. Both ABT-737 and CsAwere administered daily
from day23 to day 12; on day22 and day21, mice received 2 injections for
a total of 100 mg/kg of ABT-737 and 20 mg/kg of CsA. On day 0, ABT-737
and CsA were not administered. To monitor the deletion of donor-reactive
CD8 T cells, we adoptively transferred 203 106 syngeneic BM3.3 splenocytes
to CBA recipients before starting the conditioning protocol with B6 BM cells.
The transgenicH-2Kb reactiveBM3.3CD8T cells weremonitored over time in
peripheral blood in a fluorescence-activated cell sorter (FACS) using the
clonotypic antibody Ti98,27 kindly provided by A.-M. Schmitt-Verhulst, and
stained with a secondary phycoerythrin (PE) rat anti-mouse IgG, purchased
from Becton Dickinson (Basel, Switzerland).
Skin grafting
Mice were shaved and anesthetized with ketamine/xylazine. Full thickness
tail skin (about 1 cm2) from CBA (BM donor) or BALB/c (3rd party) mice
were grafted 3 to 6 weeks after BMT and considered rejected when,10% of
the graft remained viable. In some experiments a second skin grafting was
performed using the same procedure.
Flow cytometric analysis of chimerism and detection of
allospecific antibodies
Flow cytometric (FACS) analyses were performed with a BD-FACSCanto
(Becton Dickinson, Basel, Switzerland). Chimerism was analyzed in white
blood cells at different time points after BMT, in spleen and thymus as
indicated. Donor-derived cells were identified by fluorescein isothiocyanate
(FITC)–conjugated anti-H-2Dk or anti-H-2Kk (Becton Dickinson). The cells
were counterstained with anti-CD4-PE, anti-CD8-APC, anti-B220-PE, anti-
CD11b-APC, anti-CD11c-APC, anti-CD49b-PE (for natural killer [NK] cells)
antibodies purchased from eBioscience (Frankfurt, Germany). Background
signal measured in a naı¨ve B6 mouse was subtracted to determine the per-
centage of donor-derived cells. Allospecific antibodies were measured in
indirect FACS: CBA, and Balb/c splenocytes were incubated with recipients’
serum (1:5 dilution inFACSbuffer) and subsequently stainedwith a secondary
anti-mouse FITC-conjugated IgG antibody (eBioscience). Mean fluorescence
intensity was determined in FACS gating on CD8-positive cells.
Mixed lymphocyte reaction (MLR)
MLRwere performed in 96wells plates with responder splenocytes stimulated
by splenocytes from BM-donor, 3rd party, or syngeneic mice at a final
concentration of 43 106 cells/mL inRoswell ParkMemorial Institutemedium
containing 10% fetal bovine serum, penicillin 100 U/mL, streptomycin 100
mg/mL, and 2-mercaptoethanol 50 mM. T-cell proliferation was measured by
incorporation of 3H-thymidine (PerkinElmer, Waltham, MA) added to the
culture on day 4 after stimulation. For the selective analysis of alloreactive
CD8 T cells in vitro, BM3.3 spenocytes were stimulated with CD8 T-cell-
depleted splenocytes from B6 (allogeneic) or CBA (syngeneic) mice and
analyzed in FACS gating onCD8T cells. After cell permeabilization, the level
of different Bcl-2 factors in alloreactive CD8 T cells was detected in FACS, as
previously described.23 Bcl-2 was stained using an anti-mouse Bcl-2-PE from
Becton Dickinson, Bcl-xL with an Alexa Fluor 488 conjugated antibody from
Cell Signaling Technology (Danvers, MA). Mcl-1 was detected with a mono-
clonal rabbit anti-mouse Mcl-1 antibody from Abcam (Cambridge, United
Kingdom), Bim with a polyclonal rabbit antibody detecting total Bim (EL,
L, and S isoforms) purchased fromCell Signaling, and then stainedwith a FITC
anti-rabbit IgG (eBioscience). Splenocytes were sorted by automatic magnetic
cell separation using an autoMACS proseparator according to the protocols of
Miltenyi Biotec (Bergisch Gladbach, Germany). For polyclonal stimulation of
splenocytes, anti-CD3 and anti-CD28 antibodies were used (eBioscience).
Cell viability was measured by propidium iodide exclusion in FACS.
Statistics
Student t test was used to compare values between groups. A P value, .05
was considered significant. Graph Pad Prism Software version 5.0 (San
Diego, CA) was used for calculations.
Results
Tolerogenic effect of Bcl-2 inhibition by ABT-737
The effect of Bcl-2 inhibitors on BM engraftment and tolerance
induction was first assessed by adding a short course of ABT-737
(50 mg/kg/day, from day 23 to day 12 after BMT) to a reduced
conditioning protocol consisting of low-dose TBI (1.5 Gy) on the
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day before BMT, a single injection of anti-CD154 (MR1, 2 mg)
and 25 3 106 fully MHC-mismatched CBA BM cells to B6
recipients. ABT-737 increased the percentage of chimeric mice and
induced a higher level of chimerism in all hematopoietic cell
lineages (Figure 1A). All chimeric animals accepted donor-type
skin grafts for more than 100 days and promptly rejected third-
party grafts (BALB/c) (Figure 1B). In a second experiment, mice
were treated with the same conditioning protocol including ABT-
737, MR1, and BM cells, but without TBI. Although this protocol
was not sufficient to allow BM engraftment (Figure 1A), skin
transplantation (performed 6 weeks after BMT) revealed a marked
and lasting donor-specific hyporesponsiveness in comparison with
mice treated with MR1 and BM only (median survival time, 42 vs
96 days) (Figure 1C). Nevertheless, donor grafts were eventually
rejected (graft survival 21, 21, 54, 96, .100, .100, and .100
days). Thus, inhibition of Bcl-2, Bcl-xL, and Bcl-w was not
detrimental for survival and engraftment of donor-derived hemato-
poietic stem cells. Furthermore, ABT-737 in combination with
CD154 blockade led to some degree of donor-specific hypores-
ponsiveness, but it was not sufficient to induce stable tolerance in an
irradiation-free conditioning protocol.
We previously demonstrated that the proapoptotic effect of
ABT-737 on naı¨ve and activated lymphocytes can be potentiated in
combination with CsA.22,23 Therefore, we added a short course of
low-doseCsA (10mg/kg/day subcutaneously) to themixed chimerism
protocol introduced above (1.5GyTBI,MR1, 253106BMcells from
CBA donors). In previous studies, treatment with CsA alone had an
antitolerogenic effect and resulted in a reduced number of tolerant
mice and lower chimerism levels (Figure 2A-B).8,10,11 However, the
combination of CsA with ABT-737 completely prevented this
phenomenon and induced a high level of chimerism (Figure 2A;
supplemental Figure 1 for kinetics of multilineage chimerism) and
donor-specific tolerance in all recipients, as shown by the long-term
survival of donor-type CBA skin grafts (Figure 2B). Importantly, the
combination of ABT-737 with CsA not only prevented the anti-
tolerogenic effect of calcineurin inhibitors, it resulted in an even
higher chimerism level in comparison with ABT-737 alone, thereby
reversing the antitolerogenic effect of CsA in a paradoxical synergism
(Figure 2A). The mechanism underlying this clinically important
finding was further investigated.
The critical role of the proapoptotic factor Bim in
deletional tolerance
Because ABT-737 inhibits antiapoptotic Bcl-2 factors with high
selectivity,15 its tolerogenic effect is likely to result from a direct
interaction with the regulation of the intrinsic apoptosis pathway in
alloreactive lymphocytes. We hypothesized that ABT-737 might
reverse the antitolerogenic effect of CsA by compensating a dysregu-
lation of the intrinsic apoptosis pathway in activated CD8 T cells
determined by signal 1 inhibition.28 First, we aimed to identify an
antiapoptotic factor of the Bcl-2 familiy, whose expression in donor-
reactive T cells was reduced underMR1 alone, but not in combination
with CsA. To monitor the regulation of Bcl-2 factors in a homoge-
neous population of alloreactive CD8 T cells, we took advantage of
the BM3.3 transgenic mouse, which expresses on all CD8 T cells
a transgenic TCR specific for the MHC class I molecule H-2Kb and
can be detected by the clonotypic antibody Ti98. BM3.3 splenocytes
were stimulated with CBA (syngeneic) or B6 (allogeneic) splenocytes
under the effect of CsA and MR1 in classical MLR experiments, and
the expression of different Bcl-2 factors was measured in FACS.
Among the most important antiapoptotic Bcl-2 factors, only the
expression of Bcl-xL was reduced under the effect of MR1, but this
process was not reversed in combination with CsA (Figure 3A). This
Figure 1. ABT-737 facilitates mixed chimerism in-
duction. B6 recipients (H-2b) were treated with a condi-
tioning protocol including TBI (1.5 Gy), MR1 (2 mg), and
25 3 106 fully MHC-mismatched BM cells from CBA
donors (H-2k). Six weeks after BMT, skin transplantation
from CBA and BALB/c (3rd party, H-2d) donors was
performed. (A) Adding a short course of ABT-737 to the
conditioning regimen (ABT; 50mg/kg/day, fromday23 to
day 12 after BMT) resulted in a higher number of chimeric
animals and significantly increased the percentage of
donor-derived cells in different cell lineages in peripheral
blood leukocytes (PBL; 10 weeks after BMT). CD11b
for neutrophils; CD49b for natural killer cells; *P , .05;
**P, .01.N57. (B) After skin transplantation all chimeric
mice accepted donor grafts and promptly rejected 3rd-
party grafts, demonstrating that donor-specific tolerance
had been induced.N5 7-8 per group. (C) Using the same
experimental protocol but without TBI, we obtained a
pronounced donor-specific hyporesponsiveness, but
tolerance was not achieved, as shown by the slow
rejection of donor skin grafts over time. N 5 7-8 per
group. Representative results of 2 independent experi-
ments are shown. tpl, transplantation.
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findingwas consistent with the previously reported critical role of Bcl-
xL in thismodel,13 but did not explain the effect of CsA andABT-737.
However, we found that CsA had a major impact on the regulation of
Bim, a fundamental proapoptotic Bcl-2 factor in T cells. Alloantigen
stimulation induced a transitory upregulation of Bim in CD8 T cells
(Figure 3B). The initial upregulation phase was dependent on signal 1
(and was blocked by CsA), whereas the subsequent downregulation
was influenced by costimulatory signals. As a result, the level of Bim
remained low in cells activated in the presence of CsA, and—starting
at day 3 after stimulation—was significantly higher in CD8 T cells
treated with MR1 (Figure 3C). This correlated with the viability of
polyclonally stimulated alloreactive CD8 T cells: costimulation block-
ade did not influence alloreactive CD8 T cell viability during the first
2 days of culture (not shown), but a progressive loss of viability in
alloreactive CD8T cells devoid of costimulationwas registered at days
3 and 4 after stimulation. This process was completely dependent on
Bim, as shown in experiments using Bim2/2 CD8 T cells under the
same experimental conditions (Figure 3D). Notably, the dysregu-
lation of Bim under the effect of CsA was not influenced by MR1
(Figure 3C).
The critical role of Bim for deletional tolerance during mixed
chimerism inductionwas confirmed in vivo by applying an established
conditioning protocol (TBI 3 Gy, MR1) to Bim2/2 recipients. In
comparison with wild-type (WT) animals, Bim2/2 mice displayed
a marked resistance to mixed chimerism induction (Figure 3E). This
was reflected in skin graft survival: in Bim2/2 mice the majority of
donor-type CBA skin grafts were rejected within 50 days in
comparison with indefinite survival inWTmice (Figure 3F). Notably,
ABT-737 failed to promote tolerance when added to the same
conditioning protocol in Bim2/2 recipients (Figure 3F-G). These data
are consistent with the involvement of Bcl-xL andBim in anti-CD154-
dependent deletional tolerance, support the thesis that the antitolero-
genic effect of CsA is related to a dysregulation of Bim, and indicate
that ABT-737 promotes deletional tolerance and reverses the
antitolerogenic effect of CsA by enhancing the function of Bim. This
novel mechanism for inducing tolerance was explored to aim for
a myelosuppression-free tolerance-induction protocol.
Irradiation- and myelosuppression-free tolerance induction by
targeting the apoptosis pathway
WT B6 mice were treated with ABT-737 (50 mg/kg/day) and low-
dose CsA (10 mg/kg/day) for 2 weeks starting at day23 with respect
to BMT, and an additional dose of both drugs was administered on
day22 in order to achieve more pronounced peripheral lymphocyte
depletion. Subsequently,MR1was injected 6-12 hours before 253106
BM cells from fully MHC-mismatched CBA donors. This protocol
led to multilineage mixed chimerism in 29 out of 33 mice in 5
independent experiments. Similar to previous attempts of mixed
chimerism induction without myelosuppressive conditioning,29 the
level of donor chimerism was rather low in comparison with TBI-
based protocols (Figure 4A-B). However, chimerism remained
stable over time (supplemental Figure 2): 33 weeks after BMT,
we measured a 4.4% of donor-derived CD4, 2.7% CD8, and 15.6%
CD11b in the spleen. Interestingly, the B-cell compartment did not
show anymacrochimerism, either in the spleen or in peripheral blood
at any time point after BMT. Donor-type CBA skin grafts were
accepted indefinitely with a maximal observation time of 269 days,
whereas all third-party grafts (BALB/c) were promptly rejected,
therefore demonstrating donor-specific tolerance (Figure 4C).
Notably, the additional dose of ABT-737 on day 22 was not
sufficient to induce mixed chimerism without CsA (supplemental
Figure 3)
Although the effect of CTLA4Ig on the regulation of Bcl-2 factors
in vitro was promising (supplemental Figure 4), the success of this
protocol was dependent on inhibition of the CD40/CD154 signaling,
because the same conditioning regime failed to induce mixed
chimerism and tolerance, when MR1 was replaced by CTLA4Ig
(0.5mgonday 2 after BMT;Figure 4C). Themechanisms of tolerance
induction and maintenance in mice treated with this protocol were
further investigated.
Robust peripheral and central deletional tolerance
First, tolerization of preexisting peripheral alloreactive T cells was
assessed using the transgenic BM3.3 system described above.
Before starting the tolerance induction protocol, 20 3 106 BM3.3
splenocytes were transferred into syngeneic CBA recipients, which
allowed monitoring alloreactive BM3.3 CD8 T cells in blood over
time using the clonotypic antibody Ti98. In mice treated with the full
conditioning protocol including ABT-737 (50 mg/kg/day), low-dose
CsA (10 mg/kg/day), MR1, and 25 3 106 B6 BM cells, donor-
reactive CD8 T cells completely disappeared from the peripheral
T-cell repertoire in the first 2 weeks and did not recover after resolution
of lymphopenia (Figure 5A). In contrast, in mice treated with the
same pharmacological conditioning regimen, but without BMT,
Figure 2. ABT-737 reverses the antitolerogenic effect
of CsA. B6 recipients (H-2b) were treated with a condi-
tioning protocol including TBI (1.5 Gy), MR1 (2 mg), and
25 3 106 fully MHC-mismatched BM cells from CBA
donors (H-2k). Six weeks after BMT, skin transplantation
from CBA and BALB/c (3rd party, H-2d) donors was
performed. (A)CsA (10mg/kg/day, fromday23 to day 12
after BMT) had a deleterious impact on mixed chimerism
induction, but this effect was reversed in combination with
ABT-737 (ABT, 50 mg/kg/day, from day 23 to day 12
after BMT), as shown in the level of chimerism in different
hematopoietic cell lineages in peripheral blood leuko-
cytes (20 weeks after BMT). Notably, the chimerism level
in the combination group was even higher than in the
group treatedwithABT-737 alone. **P, .01; ***P, .001;
N5 7-8. (B) Most recipients receiving CsA alone rejected
CBA skin grafts, whereas all mice treated with a combi-
nation of CsA and ABT-737 accepted CBA and promptly
rejected BALB/c skin grafts. N 5 7-8/group.
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Ti981 cells were markedly reduced, but still detectable in peripheral
blood. The complete deletion of Ti981 cells in mice exposed to the
full protocol was confirmed by FACS analysis of the spleen after
rechallenging the recipient mice with B6 splenocytes (106 cells IV)
(Figure 5B-C). Thus, exposure to donor-derived BM cells under the
effect of MR1 and ABT-737 induced a complete peripheral deletion
Figure 3. Bim is required for induction of mixed chimerism. BM3.3 splenocytes were stimulated in vitro with CD8-depleted B6 (allo) or CBA (syn) splenocytes. The
expression of different Bcl-2 factors in transgenic alloreactive BM3.3 CD8 T cells was monitored by FACS. (A) In comparison with allostimulated cells without additional
pharmacological treatment, after 4 days of MLR, cells exposed to MR1 expressed higher levels of Bcl-2 and Mcl-1 and lower levels of Bcl-xL. The expression of these
antiapoptotic factors was not influenced by an additional treatment with CsA. Percentages of mean fluorescence intensity (MFI) values in comparison with allostimulated cells
without pharmacological treatment are shown. (B) Allostimulation induced a transient upregulation of Bim, with a peak after 2 days of culture. CsA inhibited the initial
upregulation of Bim, and MR1 prevented its downregulation in the late activation phase. (C) As a result, after 4 days the level of Bim was low in cells stimulated in the presence
of CsA and high with MR1. Statistical comparison with syn: *P , .01. (D) The relevance of these processes on CD8 T-cell viability after polyclonal stimulation was assessed
culturing WT and Bim2/2 splenocytes in the presence of anti-CD3 with anti-CD28 antibodies or without anti-CD28 and MR1. After 4 days, absence of costimulation reduced
the viability of WT CD8 T cells, but the same phenomenon was not observed using Bim2/2 cells, suggesting that the downregulation of Bim (C) was important for the viability
of activated T cells. **P , .01. (E) In vivo, a standard conditioning protocol (3 Gy TBI, MR1, 25 3 106 CBA BM cells) induced mixed chimerism in all WT B6 mice, but was not
successful in the majority of Bim2/2 mice, as shown by the levels of chimerism 15 weeks after BMT and (F) by the rejection of CBA skin grafts. Similar results were obtained if
ABT-737 was added to the same conditioning protocol (E-F). Statistical comparison WT vs Bim2/2: *P , .05; ***P , .001; N 5 6-7 per group.
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of alloreactive T cells during the mixed chimerism induction phase,
and this was not impaired by CsA.
Second, the mechanism of long-term maintenance of tolerance
was investigated in mice receiving our irradiation-free protocol.
Mixed chimeras maintain donor-specific tolerance through central
deletion of donor-reactive T cells, and the presence of donor-derived
antigen-presenting cells in the thymus is critical in this setting.30
Using the above-mentioned irradiation-free protocol, we consis-
tently detected about 5% of donor-derived antigen presenting cells
(CD11c1) in the thymus as demonstrated by thymic FACS analysis
33 weeks after BMT (Figure 6A), a finding consistent with central
clonal deletion. The presence of a sustained systemic tolerance was
further confirmed by different immunological tests: donor-specific
B-cell tolerance was demonstrated by the absence of donor-specific
IgG alloantibodies, whereas 3rd party–reactive IgG was readily
detectable several weeks after skin grafting (Figure 6B). A lack of
donor-specific T-cell responses was measured in classical MLR ex-
periments (Figure 6C), confirming at a functional level a complete
deletion of donor-reactive T cells from the peripheral repertoire.
Finally, 58 days after the first skin transplantation, tolerant mice were
rechallenged with a second skin graft from donor and 3rd-party
control. All mice accepted the secondary CBA graft and rejected the
BALB/c graft (Figure 6D-E). Taken together, a 2-week conditioning
protocol with ABT-737 and CsA in combination with MR1 induced
mixed chimerism and stable systemic T- and B-cell tolerance without
myelosuppressive treatment and with moderate doses of BM cells.
Discussion
In this study we explored the intrinsic apoptosis pathway as a novel
pharmacological target to induce mixed chimerism and allograft
tolerance. We observed a critical role of the proapoptotic Bcl-2 family
member Bim for deletional tolerance using costimulation blockade,
and we therapeutically exploited this finding using the BH3-mimetic
ABT-737 to establish a new irradiation- and myelosuppression-free
protocol to inducemixed chimerismwith amoderate dose of BMcells.
The tolerization of the peripheral T-cell compartment in mixed
chimerism induction protocols based on costimulation blockade
depends on the complex regulation of apoptosis in T cells after
antigen recognition.13 Focusing on the intrinsic pathway, the initial
upregulation of Bim is counteracted by a simultaneous regulation
of antiapoptotic factors and is required for T-cell activation.28,31
Three to 4 days after antigen-recognition stimuli by costimulatory
Figure 4. Myelosuppression-free tolerance induc-
tion with ABT-737 and CsA. B6 recipients (H-2b) were
treated with an irradiation-free conditioning protocol
including ABT-737 (50 mg/kg/day), CsA (10 mg/kg/day)
from day 23 to day 12, costimulation blockade (CSB)
with MR1 (2 mg on day 21), and 25 3 106 fully MHC-
mismatched BM cells from CBA donors (H-2k). Four to
6 weeks after BMT, skin transplantation from CBA and
BALB/c (3rd party, H-2d) donors was performed. (A-B)
A significant myeloid (CD11b1) and T-cell chimerism,
but no chimerism in the B-cell compartment, was
measured in peripheral blood (FACS at week 10 after
BMT shown in panel A) and in the spleen (FACS at 33
weeks after BMT shown in panel B). N 5 7 per group.
Representative results of 5 independent experiments
are shown. (C) Donor skin grafts were indefinitely ac-
cepted by 29 out of 33 mice in 5 independent experi-
ments, whereas 3rd-party grafts (BALB/c) were promptly
rejected. Combined data of 5 independent experiments
are shown. N5 33. The same conditioning protocol failed
to induce tolerance, when MR1 was replaced by CTLA4Ig
(0.5 mg on day 2).
Figure 5. Peripheral deletion of alloreactive CD8 T cells. Tomonitor a well-defined
population of alloreactive CD8 T cells during tolerance induction with ABT-737 and
CsA, we adoptively transferred CBA recipients (H-2k) with BM3.3 splenocytes
(transgenic TCR specific for H-2Kb on all CD8 T cells) and subsequently treated with
our irradiation-free conditioning protocol including ABT-737 (50 mg/kg/day), CsA
(10 mg/kg/day) from day23 to day 12, MR1 (2 mg), and 253 106 fully BM cells from
B6 donors (H-2b). In a control group, BM cells were not administered (conditioning
only). (A) Transgenic donor-reactive BM3.3 CD8 T cells (Ti981) were reduced in both
groups, but only in mice receiving the full protocol was a complete deletion achieved.
Statistical comparison of the 2 groups: *P , .05; **P , .01; N 5 5. (B-C) After
rechallenging with donor antigens (106 B6 splenocytes IV at day 37 after BMT), Ti981
cells were readily detectable in the conditioning-only group, but had completely
disappeared from the peripheral T-cell repertoire after exposure to the full protocol.
**P , .01; N 5 5 per group.
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molecules and interleukins are required to maintain cell survival by
a downregulation of Bim and an upregulation of Bcl-xL.32,33 In the
absence of an adequate antiapoptotic signal through costimulation,
Bim prevails and activated T cells die by apoptosis.
Bcl-2 inhibitors offer the opportunity to selectively interact with
these mechanisms. In our model, ABT-737 promoted peripheral
T-cell tolerization by at least 2 complementary effects. First, it reduced
the precursor frequency by a peripheral depletion of lymphocytes.
Second, it led to a more efficient clonal deletion of alloantigen-
reactive T cells by directly boosting the critical role of Bim in com-
bination with anti-CD154. Additional effects of Bcl-2 inhibitors on
regulatory T cells cannot be excluded. The beneficial effect of the
combination of ABT-737with CsA ismultifactorial. CsA potentiated
the proapoptotic effect of ABT-737 on lymphocytes and blocked the
upregulation of A1, thereby preventing resistance to ABT-737 in
T cells after antigen recognition.22,23 On the other hand, ABT-737
reversed the antitolerogenic effect of CsA by compensating the
missing upregulation of Bim after allostimulation under calcineurin
blockade (Figure 3). As a result, the combination of CsA and ABT-
737 resulted in a paradoxical synergistic effect. This finding is of
critical clinical relevance: because graft lost because of acute re-
jection cannot be ethically accepted in the modern transplantation
era, a clinically applicable tolerance induction protocol has to foresee
a combination of initial standard immunosuppressive and tolerance-
induction regimes in a preventive or therapeutic setting, ideally
without the a priori exclusion of calcineurin inhibitors.34
A short induction phase with ABT-737, CsA, andMR1 induced
a complete deletion of peripheral donor-reactive T cells and
allowed the engraftment of a sufficient number of donor-derived
stem cells to maintain a durable mixed hematopoietic chimerism.
Notably, because hematopoietic stem cells express high levels of
Mcl-1,35 ABT-737 does not induce apoptosis in this cell population
and is not expected to “create space” in stem cell niches, a factor that
was originally thought to be required for BM engraftment.36,37 A
significant level of chimerism without myelosuppressive condition-
ing was previously achieved using megadoses of BM, but has never
been reported using clinically applicable BM doses.29 Because our
conditioning protocol was sufficient to induce a stable level of
chimerism .5% with moderate doses of BM, we speculate that
ABT-737 and CsA might promote BM engraftment by influencing
the complex interaction of immunological, stromal, and stem cells
in the stem cell niche38 or by promoting the physiological niche
recycling.39 These aspects might assume a general relevance for
BM transplantation and the underlying mechanisms merit further
investigation.
The sustained detection of donor-derived granulocytes over more
than 8 months clearly indicated that engraftment of donor stem cells
or very early progenitor cells had occurred. However, the level of
hematopoietic chimerism was not uniform among different cell
lineages with a complete absence of donor-derived B cells and higher
levels of granulocytes. This could be explained by the engraftment of
myeloid-biased hematopoietic stem cells.40,41 The donor-derived
Figure 6. Robust, systemic tolerance after mixed chimerism induction with ABT-737 and CsA. B6 recipients were treated with an irradiation-free conditioning protocol
including ABT-737 (50 mg/kg/day), CsA (10 mg/kg/day) from day 23 to day 12, MR1 (2 mg), and 25 3 106 BM cells from CBA donors. Six weeks after BMT, skin
transplantation from CBA and BALB/c donors was performed. (A) FACS analysis 33 weeks after BMT revealed a significant percentage of donor-derived antigen-presenting
cells (CD11c1) in the thymus, but not in T cells and in T-cell precursors (DN, double negative; DP, double positive). (B) Serum samples were collected 60 days after skin
transplantation and analyzed by indirect FACS using CBA and BALB/c cells: a complete absence of CBA-reactive IgG and a normal seroconversion toward BALB/c were
measured. MFI, mean fluorescence intensity. Statistical comparison between mixed chimeras (MC) and a group of naı¨ve mice is shown. *P , .05; N 5 5. (C) Thirty-three
weeks after BMT, recipient mice were killed and their splenocytes stimulated in vitro with irradiated B6 (syn), CBA (BM donor), and BALB/c (3rd party) splenocytes in
a classical MLR. T-cell proliferation analysis, measured by 3H-thymidin incorporation, revealed a complete lack of T-cell reactivity against CBA and a normal response toward
BALB/c. CPM, counts per minute; ***P , .001; N 5 5 per group. (D) A group of mice received a second skin graft 58 days after initial transplantation. All BALB/c grafts were
rejected within 10 days, whereas CBA grafts were accepted for more than 40 days without signs of rejection. N 5 7 per group. (E) Photograph of a representative example at
day 100 after first transplantation.
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hematopoiesis was sufficient to maintain a pool of donor-derived
antigen-presenting cells in the thymus to establish central deletional
tolerance and—in a clinical perspective—may be favorable, because
it reduces the risk of graft-vs-host disease.
The tolerance induction protocol described here provides a
solution to several problems currently precluding a broad clinical
application of the mixed chimerism approach. The general toxicity
of the conditioning regimen is low in comparison with protocols
including myelosuppressive drugs or TBI.4 In phase I clinical trials,
ABT-263 displayed a favorable toxicity profile, and its application
for a short conditioning therapy seems to be adequate also for
nonmalignant conditions.21 Depleting antibodies—notably more
efficient in mice than in humans42—are not required, but a blockade
of the CD40/CD154 pathway was critical in our model. The recent
report of antibodies blocking CD40 may represent an ideal solution
for blocking this pathway without the thromboembolic side effect
reported in primates after exposure to anti-CD154.43-46 Importantly,
in contrast to previous reports of mixed chimerism induction without
myelosuppression,29,47 our conditioning protocol was successful
using a clinically relevant dose of BM cells and without additional
cell-based therapy.
In summary, we established a novel and reliable approach to
induce mixed chimerism and allograft tolerance by pharmacolog-
ical modulation of the intrinsic apoptosis pathway. This approach
allowed induction of mixed chimerism using a nontoxic, non-
myelosuppressive conditioning protocol with potential clinical
applicability.
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